



19 November 2019

The Manager  
Company Announcements  
Australian Securities Exchange  
Level 5, 20 Bridge Street  
SYDNEY NSW 2000

**By Electronic Lodgement**

Dear Sir/Madam

**Results of 2019 Annual General Meeting**

The Board of Cellmid Limited (ASX:CDY) (**Company**) is pleased to advise that shareholders of the Company **passed all Resolutions** (outlined in the table below) in the Notice of Meeting dated 18 October at the 2019 Annual General Meeting held today at 2:00pm (Sydney time) unanimously on a show of hands.

A summary of the total number of proxy votes is attached:

Yours faithfully

**Lee Tamplin**  
Company Secretary

**Cellmid Limited (ASX: CDY)**

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, USA and China. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au). Cellmid's wholly owned subsidiary, Lyramid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Lyramid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) globally.

**Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.

# Disclosure of Proxy Votes

## Cellmid Limited

Annual General Meeting

Tuesday, 19 November 2019



**Automic**

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E [hello@automic.com.au](mailto:hello@automic.com.au)

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)		
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN
1 Adoption of Remuneration Report	S	20,302,195	16,381,981	3,847,348	675,109	72,866	n/a	n/a	n/a
2 Re-election of Bruce Gordon as Director	S	29,868,787	29,133,592	658,079	702,180	77,116	n/a	n/a	n/a
3 Approval of Issue of Incentive Options to Maria Halasz, Director of the Company	S	28,542,279	22,837,593	5,627,370	8,750	77,316	n/a	n/a	n/a
4 Approval of Issue of Director Fee Shares to Dennis Eck	S	25,100,638	21,044,483	3,978,039	8,750	78,116	n/a	n/a	n/a
5 Approval of Issue of Shares to Maria Halasz, Director of the Company	S	28,542,279	23,544,785	4,919,378	8,750	78,116	n/a	n/a	n/a
6 Approval of Issue of Shares to Dennis Eck, Director of the Company	S	25,109,388	20,989,825	4,041,447	0	78,116	n/a	n/a	n/a
7 Ratification of Prior Issue of Placement Shares	S	24,683,588	21,345,272	3,257,200	1,460,018	81,116	n/a	n/a	n/a

